File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia

TitleHigh success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia
Authors
Issue Date2011
Citation
Blood, 2011, v. 118, n. 2, p. 223-230 How to Cite?
AbstractWe evaluated 190 children with very high-risk leukemia, who underwent allogeneic hematopoietic cell transplantation in 2 sequential treatment eras, to determine whether those treated with contemporary protocols had a high risk of relapse or toxic death, and whether non-HLA-identical transplantations yielded poor outcomes. For the recent cohorts, the 5-year overall survival rates were65%for the 37 patients with acute lymphoblastic leukemia and 74% for the 46 with acute myeloid leukemia; these rates compared favorably with those of earlier cohorts (28%, n = 57; and 34%, n = 50, respectively). Improvement in the recent cohorts was observed regardless of donor type (sibling, 70% vs 24%; unrelated, 61% vs 37%; and haploidentical,88%vs 19%), attributable to less infection (hazard ratio [HR] = 0.12; P = .005), regimen-related toxicity (HR = 0.25; P = .002), and leukemiarelated death (HR = 0.40; P = .01). Survival probability was dependent on leukemia status (first remission vs more advanced disease; HR = 0.63; P = .03) or minimal residual disease (positive vs negative; HR = 2.10; P = .01) at the time of transplantation. We concluded that transplantation has improved over time and should be considered for all children with very high-risk leukemia, regardless of matched donor availability. © 2011 by The American Society of Hematology.
Persistent Identifierhttp://hdl.handle.net/10722/294442
ISSN
2023 Impact Factor: 21.0
2023 SCImago Journal Rankings: 5.272
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLeung, Wing-
dc.contributor.authorCampana, Dario-
dc.contributor.authorYang, Jie-
dc.contributor.authorPei, Deqing-
dc.contributor.authorCoustan-Smith, Elaine-
dc.contributor.authorGan, Kwan-
dc.contributor.authorRubnitz, Jeffrey E.-
dc.contributor.authorSandlund, John T.-
dc.contributor.authorRibeiro, Raul C.-
dc.contributor.authorSrinivasan, Ashok-
dc.contributor.authorHartford, Christine-
dc.contributor.authorTriplett, Brandon M.-
dc.contributor.authorDallas, Mari-
dc.contributor.authorPillai, Asha-
dc.contributor.authorHandgretinger, Rupert-
dc.contributor.authorLaver, Joseph H.-
dc.contributor.authorPui, Ching Hon-
dc.date.accessioned2020-12-03T08:22:45Z-
dc.date.available2020-12-03T08:22:45Z-
dc.date.issued2011-
dc.identifier.citationBlood, 2011, v. 118, n. 2, p. 223-230-
dc.identifier.issn0006-4971-
dc.identifier.urihttp://hdl.handle.net/10722/294442-
dc.description.abstractWe evaluated 190 children with very high-risk leukemia, who underwent allogeneic hematopoietic cell transplantation in 2 sequential treatment eras, to determine whether those treated with contemporary protocols had a high risk of relapse or toxic death, and whether non-HLA-identical transplantations yielded poor outcomes. For the recent cohorts, the 5-year overall survival rates were65%for the 37 patients with acute lymphoblastic leukemia and 74% for the 46 with acute myeloid leukemia; these rates compared favorably with those of earlier cohorts (28%, n = 57; and 34%, n = 50, respectively). Improvement in the recent cohorts was observed regardless of donor type (sibling, 70% vs 24%; unrelated, 61% vs 37%; and haploidentical,88%vs 19%), attributable to less infection (hazard ratio [HR] = 0.12; P = .005), regimen-related toxicity (HR = 0.25; P = .002), and leukemiarelated death (HR = 0.40; P = .01). Survival probability was dependent on leukemia status (first remission vs more advanced disease; HR = 0.63; P = .03) or minimal residual disease (positive vs negative; HR = 2.10; P = .01) at the time of transplantation. We concluded that transplantation has improved over time and should be considered for all children with very high-risk leukemia, regardless of matched donor availability. © 2011 by The American Society of Hematology.-
dc.languageeng-
dc.relation.ispartofBlood-
dc.titleHigh success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia-
dc.typeArticle-
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1182/blood-2011-01-333070-
dc.identifier.pmid21613256-
dc.identifier.pmcidPMC3138677-
dc.identifier.scopuseid_2-s2.0-79960495326-
dc.identifier.volume118-
dc.identifier.issue2-
dc.identifier.spage223-
dc.identifier.epage230-
dc.identifier.eissn1528-0020-
dc.identifier.isiWOS:000292735100005-
dc.identifier.issnl0006-4971-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats